Bayer’s Nubeqa plus ADT granted EC approval to treat mHSPC
Nubeqa plus ADT is indicated for the treatment of people with metastatic hormone-sensitive prostate cancer (mHSPC) in the European Union (EU).

A leading resource for the Pharmaceutical industry since 2002
Nubeqa plus ADT is indicated for the treatment of people with metastatic hormone-sensitive prostate cancer (mHSPC) in the European Union (EU).
Give your business an edge with our leading industry insights.
Chemspec Europe 2025 returns to Cologne with expanded exhibition space, enhanced digital tools, and a diverse line-up of industry leaders. This premier event will showcase cutting-edge solutions across key sectors,...
Seal the deal
Excipient evolution shaping pharma innovation
Solving the EDDO guidance puzzle
AI-driven delivery